nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefpodoxime—Ceftriaxone—GLUL—liver cancer	0.0116	0.725	CrCbGaD
Cefpodoxime—Leukopenia—Sorafenib—liver cancer	0.00366	0.00372	CcSEcCtD
Cefpodoxime—Vasodilation—Doxorubicin—liver cancer	0.00364	0.0037	CcSEcCtD
Cefpodoxime—Vasodilation procedure—Doxorubicin—liver cancer	0.00364	0.0037	CcSEcCtD
Cefpodoxime—Loss of consciousness—Sorafenib—liver cancer	0.00359	0.00365	CcSEcCtD
Cefpodoxime—Cough—Sorafenib—liver cancer	0.00356	0.00362	CcSEcCtD
Cefpodoxime—Rectal haemorrhage—Doxorubicin—liver cancer	0.00354	0.00359	CcSEcCtD
Cefpodoxime—Hypertension—Sorafenib—liver cancer	0.00353	0.00358	CcSEcCtD
Cefpodoxime—Myalgia—Sorafenib—liver cancer	0.00348	0.00353	CcSEcCtD
Cefpodoxime—Vaginal inflammation—Epirubicin—liver cancer	0.00345	0.00351	CcSEcCtD
Cefpodoxime—Nocturia—Doxorubicin—liver cancer	0.00344	0.0035	CcSEcCtD
Cefpodoxime—Dry mouth—Sorafenib—liver cancer	0.0034	0.00346	CcSEcCtD
Cefpodoxime—Eructation—Epirubicin—liver cancer	0.00339	0.00345	CcSEcCtD
Cefpodoxime—Hyperkalaemia—Epirubicin—liver cancer	0.00339	0.00345	CcSEcCtD
Cefpodoxime—Anaphylactic shock—Sorafenib—liver cancer	0.00333	0.00339	CcSEcCtD
Cefpodoxime—Candida infection—Epirubicin—liver cancer	0.0033	0.00335	CcSEcCtD
Cefpodoxime—Skin exfoliation—Epirubicin—liver cancer	0.0033	0.00335	CcSEcCtD
Cefpodoxime—Shock—Sorafenib—liver cancer	0.00328	0.00333	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Sorafenib—liver cancer	0.00326	0.00332	CcSEcCtD
Cefpodoxime—Vaginal infection—Epirubicin—liver cancer	0.00326	0.00331	CcSEcCtD
Cefpodoxime—Aplastic anaemia—Epirubicin—liver cancer	0.00324	0.00329	CcSEcCtD
Cefpodoxime—Vaginal inflammation—Doxorubicin—liver cancer	0.0032	0.00325	CcSEcCtD
Cefpodoxime—Anorexia—Sorafenib—liver cancer	0.00318	0.00323	CcSEcCtD
Cefpodoxime—Hyperkalaemia—Doxorubicin—liver cancer	0.00314	0.00319	CcSEcCtD
Cefpodoxime—Eructation—Doxorubicin—liver cancer	0.00314	0.00319	CcSEcCtD
Cefpodoxime—Rash maculo-papular—Epirubicin—liver cancer	0.00314	0.00319	CcSEcCtD
Cefpodoxime—Mouth ulceration—Epirubicin—liver cancer	0.00312	0.00317	CcSEcCtD
Cefpodoxime—Candida infection—Doxorubicin—liver cancer	0.00305	0.0031	CcSEcCtD
Cefpodoxime—Skin exfoliation—Doxorubicin—liver cancer	0.00305	0.0031	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00304	0.00309	CcSEcCtD
Cefpodoxime—Vaginal infection—Doxorubicin—liver cancer	0.00302	0.00307	CcSEcCtD
Cefpodoxime—Aplastic anaemia—Doxorubicin—liver cancer	0.003	0.00305	CcSEcCtD
Cefpodoxime—Mental disability—Epirubicin—liver cancer	0.003	0.00305	CcSEcCtD
Cefpodoxime—Dyspnoea—Sorafenib—liver cancer	0.00297	0.00302	CcSEcCtD
Cefpodoxime—Dyspepsia—Sorafenib—liver cancer	0.00293	0.00298	CcSEcCtD
Cefpodoxime—Rash maculo-papular—Doxorubicin—liver cancer	0.0029	0.00295	CcSEcCtD
Cefpodoxime—Decreased appetite—Sorafenib—liver cancer	0.0029	0.00294	CcSEcCtD
Cefpodoxime—Mouth ulceration—Doxorubicin—liver cancer	0.00289	0.00294	CcSEcCtD
Cefpodoxime—Gastrointestinal disorder—Sorafenib—liver cancer	0.00288	0.00292	CcSEcCtD
Cefpodoxime—Fatigue—Sorafenib—liver cancer	0.00287	0.00292	CcSEcCtD
Cefpodoxime—Hepatic function abnormal—Epirubicin—liver cancer	0.00287	0.00291	CcSEcCtD
Cefpodoxime—Constipation—Sorafenib—liver cancer	0.00285	0.0029	CcSEcCtD
Cefpodoxime—Pain—Sorafenib—liver cancer	0.00285	0.0029	CcSEcCtD
Cefpodoxime—Mental disability—Doxorubicin—liver cancer	0.00277	0.00282	CcSEcCtD
Cefpodoxime—Cardiac failure congestive—Epirubicin—liver cancer	0.00276	0.00281	CcSEcCtD
Cefpodoxime—Gastrointestinal pain—Sorafenib—liver cancer	0.00273	0.00277	CcSEcCtD
Cefpodoxime—Dermatitis exfoliative—Epirubicin—liver cancer	0.00266	0.0027	CcSEcCtD
Cefpodoxime—Hepatic function abnormal—Doxorubicin—liver cancer	0.00265	0.0027	CcSEcCtD
Cefpodoxime—Urticaria—Sorafenib—liver cancer	0.00265	0.00269	CcSEcCtD
Cefpodoxime—Abdominal pain—Sorafenib—liver cancer	0.00264	0.00268	CcSEcCtD
Cefpodoxime—Body temperature increased—Sorafenib—liver cancer	0.00264	0.00268	CcSEcCtD
Cefpodoxime—Renal impairment—Epirubicin—liver cancer	0.00263	0.00268	CcSEcCtD
Cefpodoxime—Dermatitis bullous—Epirubicin—liver cancer	0.00262	0.00267	CcSEcCtD
Cefpodoxime—Hypoglycaemia—Epirubicin—liver cancer	0.00257	0.00261	CcSEcCtD
Cefpodoxime—Cardiac failure congestive—Doxorubicin—liver cancer	0.00256	0.0026	CcSEcCtD
Cefpodoxime—Hyponatraemia—Epirubicin—liver cancer	0.00252	0.00256	CcSEcCtD
Cefpodoxime—Migraine—Epirubicin—liver cancer	0.00247	0.00251	CcSEcCtD
Cefpodoxime—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00246	0.0025	CcSEcCtD
Cefpodoxime—Hypersensitivity—Sorafenib—liver cancer	0.00246	0.0025	CcSEcCtD
Cefpodoxime—Renal impairment—Doxorubicin—liver cancer	0.00244	0.00248	CcSEcCtD
Cefpodoxime—Dermatitis bullous—Doxorubicin—liver cancer	0.00243	0.00247	CcSEcCtD
Cefpodoxime—Face oedema—Epirubicin—liver cancer	0.00242	0.00246	CcSEcCtD
Cefpodoxime—Asthenia—Sorafenib—liver cancer	0.00239	0.00243	CcSEcCtD
Cefpodoxime—Hypoglycaemia—Doxorubicin—liver cancer	0.00238	0.00242	CcSEcCtD
Cefpodoxime—Pruritus—Sorafenib—liver cancer	0.00236	0.0024	CcSEcCtD
Cefpodoxime—Dehydration—Epirubicin—liver cancer	0.00233	0.00237	CcSEcCtD
Cefpodoxime—Hyponatraemia—Doxorubicin—liver cancer	0.00233	0.00237	CcSEcCtD
Cefpodoxime—Dry skin—Epirubicin—liver cancer	0.0023	0.00233	CcSEcCtD
Cefpodoxime—Migraine—Doxorubicin—liver cancer	0.00228	0.00232	CcSEcCtD
Cefpodoxime—Diarrhoea—Sorafenib—liver cancer	0.00228	0.00232	CcSEcCtD
Cefpodoxime—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00226	0.00229	CcSEcCtD
Cefpodoxime—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00226	0.00229	CcSEcCtD
Cefpodoxime—Face oedema—Doxorubicin—liver cancer	0.00224	0.00228	CcSEcCtD
Cefpodoxime—Gastritis—Epirubicin—liver cancer	0.00222	0.00225	CcSEcCtD
Cefpodoxime—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00221	0.00225	CcSEcCtD
Cefpodoxime—Dizziness—Sorafenib—liver cancer	0.0022	0.00224	CcSEcCtD
Cefpodoxime—Abdominal distension—Epirubicin—liver cancer	0.00218	0.00222	CcSEcCtD
Cefpodoxime—Asthma—Epirubicin—liver cancer	0.00217	0.0022	CcSEcCtD
Cefpodoxime—Dehydration—Doxorubicin—liver cancer	0.00216	0.00219	CcSEcCtD
Cefpodoxime—Eosinophilia—Epirubicin—liver cancer	0.00214	0.00218	CcSEcCtD
Cefpodoxime—Dry skin—Doxorubicin—liver cancer	0.00213	0.00216	CcSEcCtD
Cefpodoxime—Vomiting—Sorafenib—liver cancer	0.00212	0.00215	CcSEcCtD
Cefpodoxime—Rash—Sorafenib—liver cancer	0.0021	0.00214	CcSEcCtD
Cefpodoxime—Dermatitis—Sorafenib—liver cancer	0.0021	0.00213	CcSEcCtD
Cefpodoxime—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00209	0.00212	CcSEcCtD
Cefpodoxime—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00209	0.00212	CcSEcCtD
Cefpodoxime—Headache—Sorafenib—liver cancer	0.00209	0.00212	CcSEcCtD
Cefpodoxime—Bronchitis—Epirubicin—liver cancer	0.00208	0.00212	CcSEcCtD
Cefpodoxime—Pancytopenia—Epirubicin—liver cancer	0.00206	0.00209	CcSEcCtD
Cefpodoxime—Gastritis—Doxorubicin—liver cancer	0.00205	0.00209	CcSEcCtD
Cefpodoxime—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00205	0.00208	CcSEcCtD
Cefpodoxime—Neutropenia—Epirubicin—liver cancer	0.00203	0.00206	CcSEcCtD
Cefpodoxime—Dysuria—Epirubicin—liver cancer	0.00203	0.00206	CcSEcCtD
Cefpodoxime—Abdominal distension—Doxorubicin—liver cancer	0.00202	0.00205	CcSEcCtD
Cefpodoxime—Asthma—Doxorubicin—liver cancer	0.002	0.00204	CcSEcCtD
Cefpodoxime—Pollakiuria—Epirubicin—liver cancer	0.002	0.00203	CcSEcCtD
Cefpodoxime—Eosinophilia—Doxorubicin—liver cancer	0.00198	0.00202	CcSEcCtD
Cefpodoxime—Nausea—Sorafenib—liver cancer	0.00198	0.00201	CcSEcCtD
Cefpodoxime—Photosensitivity reaction—Epirubicin—liver cancer	0.00198	0.00201	CcSEcCtD
Cefpodoxime—Weight increased—Epirubicin—liver cancer	0.00197	0.002	CcSEcCtD
Cefpodoxime—Hyperglycaemia—Epirubicin—liver cancer	0.00195	0.00199	CcSEcCtD
Cefpodoxime—Pneumonia—Epirubicin—liver cancer	0.00194	0.00197	CcSEcCtD
Cefpodoxime—Bronchitis—Doxorubicin—liver cancer	0.00193	0.00196	CcSEcCtD
Cefpodoxime—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00192	0.00195	CcSEcCtD
Cefpodoxime—Pancytopenia—Doxorubicin—liver cancer	0.0019	0.00193	CcSEcCtD
Cefpodoxime—Renal failure—Epirubicin—liver cancer	0.0019	0.00193	CcSEcCtD
Cefpodoxime—Stomatitis—Epirubicin—liver cancer	0.00188	0.00191	CcSEcCtD
Cefpodoxime—Dysuria—Doxorubicin—liver cancer	0.00187	0.0019	CcSEcCtD
Cefpodoxime—Neutropenia—Doxorubicin—liver cancer	0.00187	0.0019	CcSEcCtD
Cefpodoxime—Pollakiuria—Doxorubicin—liver cancer	0.00185	0.00188	CcSEcCtD
Cefpodoxime—Haematuria—Epirubicin—liver cancer	0.00184	0.00187	CcSEcCtD
Cefpodoxime—Photosensitivity reaction—Doxorubicin—liver cancer	0.00183	0.00186	CcSEcCtD
Cefpodoxime—Weight increased—Doxorubicin—liver cancer	0.00182	0.00185	CcSEcCtD
Cefpodoxime—Epistaxis—Epirubicin—liver cancer	0.00182	0.00185	CcSEcCtD
Cefpodoxime—Sinusitis—Epirubicin—liver cancer	0.00181	0.00184	CcSEcCtD
Cefpodoxime—Hyperglycaemia—Doxorubicin—liver cancer	0.00181	0.00184	CcSEcCtD
Cefpodoxime—Agranulocytosis—Epirubicin—liver cancer	0.0018	0.00183	CcSEcCtD
Cefpodoxime—Pneumonia—Doxorubicin—liver cancer	0.0018	0.00183	CcSEcCtD
Cefpodoxime—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00177	0.0018	CcSEcCtD
Cefpodoxime—Renal failure—Doxorubicin—liver cancer	0.00176	0.00179	CcSEcCtD
Cefpodoxime—Haemoglobin—Epirubicin—liver cancer	0.00174	0.00177	CcSEcCtD
Cefpodoxime—Stomatitis—Doxorubicin—liver cancer	0.00174	0.00177	CcSEcCtD
Cefpodoxime—Rhinitis—Epirubicin—liver cancer	0.00174	0.00177	CcSEcCtD
Cefpodoxime—Haemorrhage—Epirubicin—liver cancer	0.00173	0.00176	CcSEcCtD
Cefpodoxime—Oedema peripheral—Epirubicin—liver cancer	0.00171	0.00174	CcSEcCtD
Cefpodoxime—Haematuria—Doxorubicin—liver cancer	0.0017	0.00173	CcSEcCtD
Cefpodoxime—Epistaxis—Doxorubicin—liver cancer	0.00169	0.00171	CcSEcCtD
Cefpodoxime—Sinusitis—Doxorubicin—liver cancer	0.00168	0.0017	CcSEcCtD
Cefpodoxime—Agranulocytosis—Doxorubicin—liver cancer	0.00167	0.0017	CcSEcCtD
Cefpodoxime—Erythema multiforme—Epirubicin—liver cancer	0.00164	0.00167	CcSEcCtD
Cefpodoxime—Tinnitus—Epirubicin—liver cancer	0.00162	0.00164	CcSEcCtD
Cefpodoxime—Haemoglobin—Doxorubicin—liver cancer	0.00161	0.00164	CcSEcCtD
Cefpodoxime—Rhinitis—Doxorubicin—liver cancer	0.00161	0.00163	CcSEcCtD
Cefpodoxime—Haemorrhage—Doxorubicin—liver cancer	0.0016	0.00163	CcSEcCtD
Cefpodoxime—Oedema peripheral—Doxorubicin—liver cancer	0.00158	0.00161	CcSEcCtD
Cefpodoxime—Chills—Epirubicin—liver cancer	0.00156	0.00158	CcSEcCtD
Cefpodoxime—Alopecia—Epirubicin—liver cancer	0.00153	0.00156	CcSEcCtD
Cefpodoxime—Erythema multiforme—Doxorubicin—liver cancer	0.00152	0.00154	CcSEcCtD
Cefpodoxime—Tinnitus—Doxorubicin—liver cancer	0.0015	0.00152	CcSEcCtD
Cefpodoxime—Flatulence—Epirubicin—liver cancer	0.00149	0.00151	CcSEcCtD
Cefpodoxime—Tension—Epirubicin—liver cancer	0.00148	0.00151	CcSEcCtD
Cefpodoxime—Dysgeusia—Epirubicin—liver cancer	0.00148	0.0015	CcSEcCtD
Cefpodoxime—Nervousness—Epirubicin—liver cancer	0.00147	0.00149	CcSEcCtD
Cefpodoxime—Back pain—Epirubicin—liver cancer	0.00146	0.00148	CcSEcCtD
Cefpodoxime—Chills—Doxorubicin—liver cancer	0.00144	0.00146	CcSEcCtD
Cefpodoxime—Alopecia—Doxorubicin—liver cancer	0.00142	0.00144	CcSEcCtD
Cefpodoxime—Ill-defined disorder—Epirubicin—liver cancer	0.0014	0.00142	CcSEcCtD
Cefpodoxime—Anaemia—Epirubicin—liver cancer	0.0014	0.00142	CcSEcCtD
Cefpodoxime—Agitation—Epirubicin—liver cancer	0.00139	0.00141	CcSEcCtD
Cefpodoxime—Flatulence—Doxorubicin—liver cancer	0.00138	0.0014	CcSEcCtD
Cefpodoxime—Tension—Doxorubicin—liver cancer	0.00137	0.00139	CcSEcCtD
Cefpodoxime—Dysgeusia—Doxorubicin—liver cancer	0.00137	0.00139	CcSEcCtD
Cefpodoxime—Malaise—Epirubicin—liver cancer	0.00136	0.00138	CcSEcCtD
Cefpodoxime—Nervousness—Doxorubicin—liver cancer	0.00136	0.00138	CcSEcCtD
Cefpodoxime—Vertigo—Epirubicin—liver cancer	0.00136	0.00138	CcSEcCtD
Cefpodoxime—Syncope—Epirubicin—liver cancer	0.00135	0.00138	CcSEcCtD
Cefpodoxime—Leukopenia—Epirubicin—liver cancer	0.00135	0.00137	CcSEcCtD
Cefpodoxime—Back pain—Doxorubicin—liver cancer	0.00135	0.00137	CcSEcCtD
Cefpodoxime—Palpitations—Epirubicin—liver cancer	0.00133	0.00136	CcSEcCtD
Cefpodoxime—Loss of consciousness—Epirubicin—liver cancer	0.00133	0.00135	CcSEcCtD
Cefpodoxime—Cough—Epirubicin—liver cancer	0.00132	0.00134	CcSEcCtD
Cefpodoxime—Convulsion—Epirubicin—liver cancer	0.00131	0.00133	CcSEcCtD
Cefpodoxime—Hypertension—Epirubicin—liver cancer	0.0013	0.00132	CcSEcCtD
Cefpodoxime—Ill-defined disorder—Doxorubicin—liver cancer	0.0013	0.00132	CcSEcCtD
Cefpodoxime—Anaemia—Doxorubicin—liver cancer	0.00129	0.00131	CcSEcCtD
Cefpodoxime—Chest pain—Epirubicin—liver cancer	0.00129	0.00131	CcSEcCtD
Cefpodoxime—Myalgia—Epirubicin—liver cancer	0.00129	0.00131	CcSEcCtD
Cefpodoxime—Agitation—Doxorubicin—liver cancer	0.00128	0.0013	CcSEcCtD
Cefpodoxime—Anxiety—Epirubicin—liver cancer	0.00128	0.0013	CcSEcCtD
Cefpodoxime—Discomfort—Epirubicin—liver cancer	0.00127	0.00129	CcSEcCtD
Cefpodoxime—Malaise—Doxorubicin—liver cancer	0.00126	0.00128	CcSEcCtD
Cefpodoxime—Dry mouth—Epirubicin—liver cancer	0.00126	0.00128	CcSEcCtD
Cefpodoxime—Vertigo—Doxorubicin—liver cancer	0.00125	0.00128	CcSEcCtD
Cefpodoxime—Syncope—Doxorubicin—liver cancer	0.00125	0.00127	CcSEcCtD
Cefpodoxime—Leukopenia—Doxorubicin—liver cancer	0.00125	0.00127	CcSEcCtD
Cefpodoxime—Cefazolin—ALB—liver cancer	0.00125	0.0778	CrCbGaD
Cefpodoxime—Confusional state—Epirubicin—liver cancer	0.00124	0.00126	CcSEcCtD
Cefpodoxime—Palpitations—Doxorubicin—liver cancer	0.00123	0.00125	CcSEcCtD
Cefpodoxime—Anaphylactic shock—Epirubicin—liver cancer	0.00123	0.00125	CcSEcCtD
Cefpodoxime—Loss of consciousness—Doxorubicin—liver cancer	0.00123	0.00125	CcSEcCtD
Cefpodoxime—Cough—Doxorubicin—liver cancer	0.00122	0.00124	CcSEcCtD
Cefpodoxime—Shock—Epirubicin—liver cancer	0.00121	0.00123	CcSEcCtD
Cefpodoxime—Convulsion—Doxorubicin—liver cancer	0.00121	0.00123	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Epirubicin—liver cancer	0.00121	0.00123	CcSEcCtD
Cefpodoxime—Hypertension—Doxorubicin—liver cancer	0.00121	0.00123	CcSEcCtD
Cefpodoxime—Hyperhidrosis—Epirubicin—liver cancer	0.00119	0.00121	CcSEcCtD
Cefpodoxime—Chest pain—Doxorubicin—liver cancer	0.00119	0.00121	CcSEcCtD
Cefpodoxime—Myalgia—Doxorubicin—liver cancer	0.00119	0.00121	CcSEcCtD
Cefpodoxime—Anxiety—Doxorubicin—liver cancer	0.00119	0.0012	CcSEcCtD
Cefpodoxime—Ceftriaxone—ALB—liver cancer	0.00118	0.0738	CrCbGaD
Cefpodoxime—Discomfort—Doxorubicin—liver cancer	0.00117	0.00119	CcSEcCtD
Cefpodoxime—Anorexia—Epirubicin—liver cancer	0.00117	0.00119	CcSEcCtD
Cefpodoxime—Dry mouth—Doxorubicin—liver cancer	0.00116	0.00118	CcSEcCtD
Cefpodoxime—Hypotension—Epirubicin—liver cancer	0.00115	0.00117	CcSEcCtD
Cefpodoxime—Confusional state—Doxorubicin—liver cancer	0.00115	0.00117	CcSEcCtD
Cefpodoxime—Anaphylactic shock—Doxorubicin—liver cancer	0.00114	0.00116	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00112	0.00114	CcSEcCtD
Cefpodoxime—Shock—Doxorubicin—liver cancer	0.00112	0.00114	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Doxorubicin—liver cancer	0.00112	0.00113	CcSEcCtD
Cefpodoxime—Insomnia—Epirubicin—liver cancer	0.00111	0.00113	CcSEcCtD
Cefpodoxime—Paraesthesia—Epirubicin—liver cancer	0.00111	0.00112	CcSEcCtD
Cefpodoxime—Hyperhidrosis—Doxorubicin—liver cancer	0.0011	0.00112	CcSEcCtD
Cefpodoxime—Dyspnoea—Epirubicin—liver cancer	0.0011	0.00112	CcSEcCtD
Cefpodoxime—Somnolence—Epirubicin—liver cancer	0.0011	0.00111	CcSEcCtD
Cefpodoxime—Anorexia—Doxorubicin—liver cancer	0.00109	0.0011	CcSEcCtD
Cefpodoxime—Dyspepsia—Epirubicin—liver cancer	0.00108	0.0011	CcSEcCtD
Cefpodoxime—Decreased appetite—Epirubicin—liver cancer	0.00107	0.00109	CcSEcCtD
Cefpodoxime—Hypotension—Doxorubicin—liver cancer	0.00107	0.00108	CcSEcCtD
Cefpodoxime—Gastrointestinal disorder—Epirubicin—liver cancer	0.00106	0.00108	CcSEcCtD
Cefpodoxime—Fatigue—Epirubicin—liver cancer	0.00106	0.00108	CcSEcCtD
Cefpodoxime—Pain—Epirubicin—liver cancer	0.00105	0.00107	CcSEcCtD
Cefpodoxime—Constipation—Epirubicin—liver cancer	0.00105	0.00107	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00104	0.00106	CcSEcCtD
Cefpodoxime—Cefalotin—ALB—liver cancer	0.00103	0.0646	CrCbGaD
Cefpodoxime—Insomnia—Doxorubicin—liver cancer	0.00103	0.00105	CcSEcCtD
Cefpodoxime—Paraesthesia—Doxorubicin—liver cancer	0.00102	0.00104	CcSEcCtD
Cefpodoxime—Dyspnoea—Doxorubicin—liver cancer	0.00102	0.00103	CcSEcCtD
Cefpodoxime—Feeling abnormal—Epirubicin—liver cancer	0.00102	0.00103	CcSEcCtD
Cefpodoxime—Somnolence—Doxorubicin—liver cancer	0.00101	0.00103	CcSEcCtD
Cefpodoxime—Gastrointestinal pain—Epirubicin—liver cancer	0.00101	0.00102	CcSEcCtD
Cefpodoxime—Dyspepsia—Doxorubicin—liver cancer	0.001	0.00102	CcSEcCtD
Cefpodoxime—Decreased appetite—Doxorubicin—liver cancer	0.000991	0.00101	CcSEcCtD
Cefpodoxime—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000984	0.001	CcSEcCtD
Cefpodoxime—Fatigue—Doxorubicin—liver cancer	0.000983	0.000999	CcSEcCtD
Cefpodoxime—Urticaria—Epirubicin—liver cancer	0.000979	0.000995	CcSEcCtD
Cefpodoxime—Pain—Doxorubicin—liver cancer	0.000975	0.000991	CcSEcCtD
Cefpodoxime—Constipation—Doxorubicin—liver cancer	0.000975	0.000991	CcSEcCtD
Cefpodoxime—Body temperature increased—Epirubicin—liver cancer	0.000974	0.00099	CcSEcCtD
Cefpodoxime—Abdominal pain—Epirubicin—liver cancer	0.000974	0.00099	CcSEcCtD
Cefpodoxime—Cephalexin—ALB—liver cancer	0.00094	0.0588	CrCbGaD
Cefpodoxime—Feeling abnormal—Doxorubicin—liver cancer	0.000939	0.000955	CcSEcCtD
Cefpodoxime—Gastrointestinal pain—Doxorubicin—liver cancer	0.000932	0.000947	CcSEcCtD
Cefpodoxime—Hypersensitivity—Epirubicin—liver cancer	0.000908	0.000922	CcSEcCtD
Cefpodoxime—Urticaria—Doxorubicin—liver cancer	0.000906	0.00092	CcSEcCtD
Cefpodoxime—Abdominal pain—Doxorubicin—liver cancer	0.000901	0.000916	CcSEcCtD
Cefpodoxime—Body temperature increased—Doxorubicin—liver cancer	0.000901	0.000916	CcSEcCtD
Cefpodoxime—Asthenia—Epirubicin—liver cancer	0.000884	0.000898	CcSEcCtD
Cefpodoxime—Pruritus—Epirubicin—liver cancer	0.000872	0.000886	CcSEcCtD
Cefpodoxime—Diarrhoea—Epirubicin—liver cancer	0.000843	0.000857	CcSEcCtD
Cefpodoxime—Hypersensitivity—Doxorubicin—liver cancer	0.00084	0.000854	CcSEcCtD
Cefpodoxime—Asthenia—Doxorubicin—liver cancer	0.000818	0.000831	CcSEcCtD
Cefpodoxime—Dizziness—Epirubicin—liver cancer	0.000815	0.000828	CcSEcCtD
Cefpodoxime—Pruritus—Doxorubicin—liver cancer	0.000806	0.00082	CcSEcCtD
Cefpodoxime—Vomiting—Epirubicin—liver cancer	0.000783	0.000796	CcSEcCtD
Cefpodoxime—Diarrhoea—Doxorubicin—liver cancer	0.00078	0.000793	CcSEcCtD
Cefpodoxime—Rash—Epirubicin—liver cancer	0.000777	0.000789	CcSEcCtD
Cefpodoxime—Dermatitis—Epirubicin—liver cancer	0.000776	0.000789	CcSEcCtD
Cefpodoxime—Headache—Epirubicin—liver cancer	0.000772	0.000784	CcSEcCtD
Cefpodoxime—Dizziness—Doxorubicin—liver cancer	0.000754	0.000766	CcSEcCtD
Cefpodoxime—Nausea—Epirubicin—liver cancer	0.000732	0.000744	CcSEcCtD
Cefpodoxime—Vomiting—Doxorubicin—liver cancer	0.000725	0.000737	CcSEcCtD
Cefpodoxime—Rash—Doxorubicin—liver cancer	0.000719	0.00073	CcSEcCtD
Cefpodoxime—Dermatitis—Doxorubicin—liver cancer	0.000718	0.00073	CcSEcCtD
Cefpodoxime—Headache—Doxorubicin—liver cancer	0.000714	0.000726	CcSEcCtD
Cefpodoxime—Nausea—Doxorubicin—liver cancer	0.000677	0.000688	CcSEcCtD
